Clene Secures $28M+ Financing Above Market, Advances ALS Drug Towards FDA NDA Filing

summarizeSummary

Clene Inc. announced full year 2025 financial results, a significant oversubscribed financing priced above market, and critical progress towards an FDA NDA filing for its ALS drug candidate, CNM-Au8®.

check_boxKey Events

• Significant Financing Secured

  Clene announced an oversubscribed registered direct offering of over $28 million, priced above market. The initial tranche of over $6 million provides operating runway to the end of Q3 2026, with additional tranches expected to extend capital into 2027.

• Key FDA Regulatory Progress for ALS Drug

  A Type C FDA meeting is scheduled by the end of Q1 2026 to discuss CNM-Au8® data for ALS, with formal written minutes expected early Q2 2026. The company plans to file an NDA under an accelerated approval pathway by the end of June 2026.

• Positive Biomarker and Safety Data

  Completed FDA-recommended biomarker analyses demonstrated statistically significant reductions in NfL and GFAP, linked to improved survival. CNM-Au8® also maintains a favorable safety profile across over 1,100 patient years of exposure.

• Full Year 2025 Financial Results

  The company reported a net loss of $26.2 million, or $2.65 per share, for the year ended December 31, 2025, a reduction from the $39.4 million net loss in 2024. Cash and cash equivalents totaled $5.2 million as of December 31, 2025.

auto_awesomeAnalysis

This filing is highly significant for Clene Inc., a clinical-stage biopharmaceutical company. The successful completion of an oversubscribed registered direct offering of over $28 million, notably priced above market, provides crucial capital and signals strong investor confidence. This financing extends the company's cash runway, with the initial tranche funding operations through a potential FDA NDA acceptance decision and subsequent tranches extending into 2027. Concurrently, the company is making substantial regulatory progress for its CNM-Au8® program for ALS, with a Type C FDA meeting scheduled and plans to file an NDA under an accelerated approval pathway by the end of Q2 2026. Positive biomarker data further supports this regulatory path. While the company reported a net loss for 2025, the reduced loss compared to 2024 and the critical financing and regulatory milestones significantly de-risk the company's near-term future.